Press release
Future of the Renin-Angiotensin-System (RAS)-Acting Agents Market: Strategic Analysis and Forecast to 2034
Renin-Angiotensin-System (RAS)-Acting Agents Market
Renin-Angiotensin-System (RAS)-Acting Agents Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
There has been consistent expansion in the market size of renin-angiotensin-system (RAS)-acting agents in the past few years. The market is projected to increase from $5.82 billion in 2024 to $6.11 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.0%. The underlying reasons for growth in the historical period are tied to factors such as escalating hypertension cases, a surge in cardiovascular disease incidents, the rise in the elderly population, heightened awareness about blood pressure regulation, robust clinical research backing, and the authorization of new drugs.
Renin-Angiotensin-System (RAS)-Acting Agents Market Size Forecast: What's the Projected Valuation by 2029?
Expect a solid surge in growth for the renin-angiotensin-system (RAS)-acting agents market over the upcoming years. The market is predicted to swell to "$7.55 billion by 2029", expanding at a compound annual growth rate (CAGR) of 5.4%. Increased concentration on bespoke treatment, enhanced demand for fixed-dose combinations, greater investment in cardiovascular study, improved healthcare accessibility in burgeoning markets, and escalating incidence of diseases tied to modern living contribute to the market's growth during the forecast period. Key trends projected for this period include the use of artificial intelligence (AI) in drug development, delivery of drugs via nanotechnology, advancements in personalized medicine, the application of blockchain for secure clinical data, utilization of wearable biosensors in monitoring hypertension, and the implementation of digital twin technology in patient modeling.
View the full report here:
https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report
What Are the Drivers Transforming the Renin-Angiotensin-System (RAS)-Acting Agents Market?
As the incidence of hypertension rises, it is likely to fuel the advancement of the renin-angiotensin system (RAS)-acting agents market. Hypertension, often referred to as high blood pressure, is a persistent medical issue where the blood's force against the arterial walls remains excessively high. This growing prevalence can be attributed to unhealthy eating habits involving high salt intake and processed foods, leading to increased blood pressure and strains the heart and blood vessels. This is where renin-angiotensin system (RAS)-acting agents come into the picture - they aid in controlling blood pressure by inhibiting angiotensin II, a hormone responsible for narrowing blood vessels and fluid retention, thus stimulating vasodilation and blood pressure reduction. For instance, the Australian Bureau of Statistics, a governmental unit based in Australia, reported in October 2024 that approximately 11.6% (equivalent to 3.0 million) Australians had hypertension in 2022, with comparable rates among males (11.7%) and females (11.6%). Hence, the growing incidence of hypertension is prompting the expansion of the renin-angiotensin system (RAS)-acting agents market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp
What Trends Will Shape the Renin-Angiotensin-System (RAS)-Acting Agents Market Through 2029 and Beyond?
Dominant enterprises in the renin-angiotensin system (RAS)-acting agents market are concentrating efforts on the creation of new renin-angiotensin system (RAS) inhibitors like angiotensin-converting enzyme (ACE) inhibitors. These are aimed at enhancing effectiveness, reducing side effects, promoting patient adherence, and addressing hypertension, heart failure and kidney diseases. An ACE inhibitor is a drug that controls blood pressure by inhibiting the enzyme that changes angiotensin I into angiotensin II, a compound that constricts blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharma corporation, was granted a Pediatric use Marketing Authorization (PUMA) by the European Commission for Aqumeldi (enalapril maleate) orodispersible tablets. They are indicated for the management of heart failure in children ranging from newborns to under 18 years of age. Aqumeldi, an ACE inhibitor, aids pediatric heart patients by restraining the ACE, blocking the transformation of angiotensin I to angiotensin II. This eases blood vessels, betters blood flow, and reduces stress on the heart.
Which Segments in the Renin-Angiotensin-System (RAS)-Acting Agents Market Offer the Most Profit Potential?
The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented -
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone, Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp
Which Firms Dominate the Renin-Angiotensin-System (RAS)-Acting Agents Market by Market Share and Revenue in 2025?
Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.
Which Regions Offer the Highest Growth Potential in the Renin-Angiotensin-System (RAS)-Acting Agents Market?
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Future of the Renin-Angiotensin-System (RAS)-Acting Agents Market: Strategic Analysis and Forecast to 2034 here
News-ID: 4184133 • Views: …
More Releases from The Business Research Company
Growing Cardiovascular Disease Cases Fueling The Growth Of The Market Due To Ris …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Blood Based Biomarkers Market Through 2025?
The market size for blood-based biomarkers has seen swift growth in the previous years. The market, which stands at $23.13 billion in 2024, is projected to increase to $25.83 billion by 2025, exhibiting a Compound Annual…
Autoimmune Gastrointestinal Dysmotility Market Growth Accelerates: Strategic For …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Autoimmune Gastrointestinal Dysmotility Industry Market Size Be by 2025?
The market for autoimmune gastrointestinal dysmotility has seen consistent expansion in the past few years. The growth is expected to continue from $1.73 billion in 2024 to $1.82 billion in 2025, with a compound annual growth rate…
The Rising Prevalence Of Chronic Diseases Is Fueling The Market Growth Due To In …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Appetite Stimulant Market Size By 2025?
The market for appetite stimulants has experienced significant growth in the past few years. Its size is expected to increase from $1.75 billion in 2024 to $1.9 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.2%.…
Key Trends Influencing the Growth of the Intravenous Iron Drugs Market in 2025: …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Intravenous Iron Drugs Market Through 2025?
The market for intravenous iron drugs has seen a swift expansion in its size over the last few years. The market, which was at $3.44 billion in 2024, is forecasted to reach $3.81 billion in 2025,…
More Releases for RAS
Ras Al Khaimah's Trusted Physiotherapy Service
Unlock Your Body's Potential with Physio Home Professional Physiotherapy Services
At Physio Home in Ras Al Khaimah, we understand the pivotal role that physiotherapy plays in enhancing one's quality of life. Our dedicated team of experts is committed to providing personalized care and effective solutions tailored to your unique needs. With a focus on empowering mobility and promoting holistic well-being, we bring top-tier physiotherapy services directly to your doorstep. Whether you're…
Ras Aquaculture Market Leading Players, Competitive Landscape, Strategy, Forecas …
Ras Aquaculture Market Overview:
Recirculating Aquaculture Systems (RAS) represent an innovative and sustainable approach to aquaculture, focusing on the intensive farming of aquatic organisms in a controlled environment. Unlike traditional aquaculture methods that rely heavily on large water bodies, RAS involves the continuous recirculation and treatment of water within a closed-loop system. This method significantly reduces water usage, minimizes environmental impact, and allows for year-round production regardless of external weather conditions.…
RAS Inhibitors Market Size, Share, Growth Analysis 2023
The global ras inhibitors market size was valued at USD x billion in 2022 and is poised to grow at a significant CAGR of x% during the forecast period 2023-29. Ongoing research and development efforts in the RAS-inhibitors agents market are expanding its scope. New drugs targeting various renin-angiotensin system components, such as renin, ACE, and angiotensin II receptors, are being explored. The market is also witnessing increased interest…
RAS Targeting Therapies Market, 2021-2031 by Roots
Roots Analysis has announced the addition of “RAS Targeting Therapies Market, 2021-2031” report to its list of offerings.
To order this 140+ page report, which features 95+ figures, please visit https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html
Key Inclusions
A detailed overview of the current market landscape of RAS targeting therapies, along with information on several relevant parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I /…
RAS Luxury Oils Launches Eco drive Campaign
Luxury Natural Skincare and wellness brand promotes Sustainability for the Environment
One Bottle at a Time #RecyclewithRAS
New Delhi, 26th November 2018: “Farm to bottle’ luxury natural skincare and wellness brand RAS Luxury Oils has launched its eco drive campaign, #RecyclewithRAS to encourage customers, to promote the concept of three R’s -“Reduce, Reuse and Recycle”, and to regain the sustainability of the packaging among customers.
On returning 1 empty primary bottle…
The Kurchatov Institute Has Chosen 2X RAS
Kurchatov Institute - supported by Aflex Distribution - Has Chosen 2X Remote Application Server
"We are very positive about the adoption of a 2X solution. At the moment we are using 2X RAS for its main features: application delivery and load balancing. We are very satisfied with the seamless end-user experience and the high availability gained with the workload-based server load balancing. In future, we plan to use 2X RAS…
